Record mula sa primary source
Decision-gradeTopline na resulta
Iniulat ng Aquestive ang positibong resulta ng pag-aaral sa human factors at PK ng Anaphylm
Inihayag ng kumpanya ang positibong resulta mula sa human factors validation study at pharmacokinetic study nito para sa Anaphylm sublingual film. Sinusuportahan ng mga datos na ito ang planadong muling pagsusumite ng NDA sa FDA para sa paggamot ng Type 1 allergic reactions, kasama ang anaphylaxis.
Mahahalagang fact
- Na-file
- Ago 10, 2026, 11:05 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
AQSTAquestive- Asset
- epinephrine
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Kalendaryo
- Resulta ng trial · Hul 1, 2026 · Positibo
Sipi mula sa source
aqst-20260810 0001398733 false 0001398733 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2026 Aquestive Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-38599 82-3827296 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 30 Technology Drive Warren , NJ 07059 ( 908 ) 941-1900 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Not Applicable (Former name or former address, if changed since last report) ______________________
Higit pa tungkol sa asset na ito
Decision-grade
May 13, 2026
08:04 PM
AQSTAquestiveMateryal
Mar 30, 2026
11:44 AM
AQSTAquestiveDecision-grade
Ene 9, 2026
12:18 PM
AQSTAquestiveDecision-grade
Nob 5, 2025
09:04 PM
AQSTAquestiveKapansin-pansin
Okt 8, 2025
11:23 AM
AQSTAquestiveAquestive: dalawang bagong patent ang nagpapahaba ng proteksyon ng Anaphylm hanggang 2037